CHRISTOPHER MCFADDEN: Open Payments
NPI 1982247417 · ZANESVILLE, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,655 in 156 payments from 18 companies in 2025. Trend: 2023 $2,158 · 2024 $2,650 · 2025 $2,655
Food & beverage: $2,655
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 23 | $385 |
| Alkermes, Inc. | 19 | $332 |
| E.R. Squibb & Sons, L.L.C. | 14 | $307 |
| Supernus Pharmaceuticals, Inc. | 20 | $245 |
| Lundbeck LLC | 14 | $227 |
| Teva Pharmaceuticals USA, Inc. | 14 | $223 |
| ABBVIE INC. | 12 | $186 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $184 |
| Tris Pharma Inc | 5 | $88 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
Products named: INGREZZA, ARISTADA, COBENFY, Qelbree, REXULTI, VRAYLAR, CAPLYTA, UZEDY.
Industry payments across OH — which companies pay providers there.
